Reviews - 1qib mentioned but not cited (3)
- Application of structural dynamic approaches provide novel insights into the enzymatic mechanism of the tumor necrosis factor-alpha-converting enzyme. Sagi I, Milla ME. Anal. Biochem. 372 1-10 (2008)
- Peripheral membrane associations of matrix metalloproteinases. Van Doren SR, Marcink TC, Koppisetti RK, Jurkevich A, Fulcher YG. Biochim Biophys Acta Mol Cell Res 1864 1964-1973 (2017)
- Inhibitory Antibodies Designed for Matrix Metalloproteinase Modulation. Fischer T, Riedl R. Molecules 24 (2019)
Articles - 1qib mentioned but not cited (26)
- POVME: an algorithm for measuring binding-pocket volumes. Durrant JD, de Oliveira CA, McCammon JA. J. Mol. Graph. Model. 29 773-776 (2011)
- Zinc-binding groups modulate selective inhibition of MMPs. Agrawal A, Romero-Perez D, Jacobsen JA, Villarreal FJ, Cohen SM. ChemMedChem 3 812-820 (2008)
- Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2): identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP-1)). Bahudhanapati H, Zhang Y, Sidhu SS, Brew K. J. Biol. Chem. 286 31761-31770 (2011)
- Structural basis for matrix metalloproteinase-2 (MMP-2)-selective inhibitory action of β-amyloid precursor protein-derived inhibitor. Hashimoto H, Takeuchi T, Komatsu K, Miyazaki K, Sato M, Higashi S. J. Biol. Chem. 286 33236-33243 (2011)
- Anacardic acid inhibits the catalytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9. Omanakuttan A, Nambiar J, Harris RM, Bose C, Pandurangan N, Varghese RK, Kumar GB, Tainer JA, Banerji A, Perry JJ, Nair BG. Mol. Pharmacol. 82 614-622 (2012)
- A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity. Lukacova V, Zhang Y, Kroll DM, Raha S, Comez D, Balaz S. J. Med. Chem. 48 2361-2370 (2005)
- Including receptor flexibility and induced fit effects into the design of MMP-2 inhibitors. Durrant JD, de Oliveira CA, McCammon JA. J. Mol. Recognit. 23 173-182 (2010)
- Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1' loop canonical conformation. Devel L, Garcia S, Czarny B, Beau F, LaJeunesse E, Vera L, Georgiadis D, Stura E, Dive V. J. Biol. Chem. 285 35900-35909 (2010)
- Characterization of Ca2+ interactions with matrix metallopeptidase-12: implications for matrix metallopeptidase regulation. Gossas T, Danielson UH. Biochem. J. 398 393-398 (2006)
- Mechanism of proteolysis in matrix metalloproteinase-2 revealed by QM/MM modeling. Vasilevskaya T, Khrenova MG, Nemukhin AV, Thiel W. J Comput Chem 36 1621-1630 (2015)
- Resveratrol inhibits matrix metalloproteinases to attenuate neuronal damage in cerebral ischemia: a molecular docking study exploring possible neuroprotection. Pandey AK, Bhattacharya P, Shukla SC, Paul S, Patnaik R. Neural Regen Res 10 568-575 (2015)
- Pyrone-based inhibitors of metalloproteinase types 2 and 3 may work as conformation-selective inhibitors. Durrant JD, de Oliveira CA, McCammon JA. Chem Biol Drug Des 78 191-198 (2011)
- Crystallization and preliminary X-ray crystallographic analysis of the catalytic domain of membrane type 1 matrix metalloproteinase. Ogata H, Decaneto E, Grossman M, Havenith M, Sagi I, Lubitz W, Knipp M. Acta Crystallogr F Struct Biol Commun 70 232-235 (2014)
- Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E, Margarida Bernardo M, Fridman R, Da Settimo F, Martini C, Rossello A. Eur J Med Chem 46 2617-2629 (2011)
- Molecular Docking Analysis of Selected Clinacanthus nutans Constituents as Xanthine Oxidase, Nitric Oxide Synthase, Human Neutrophil Elastase, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9 and Squalene Synthase Inhibitors. Narayanaswamy R, Isha A, Wai LK, Ismail IS. Pharmacogn Mag 12 S21-6 (2016)
- Amino Acid derivatives as new zinc binding groups for the design of selective matrix metalloproteinase inhibitors. Giustiniano M, Tortorella P, Agamennone M, Di Pizio A, Rossello A, Nuti E, Gomez-Monterrey I, Novellino E, Campiglia P, Vernieri E, Sala M, Bertamino A, Carotenuto A. J Amino Acids 2013 178381 (2013)
- An integrated computational approach to rationalize the activity of non-zinc-binding MMP-2 inhibitors. Di Pizio A, Agamennone M, Aschi M. PLoS ONE 7 e47774 (2012)
- Analysis of X-ray structures of matrix metalloproteinases via chaotic map clustering. Giangreco I, Nicolotti O, Carotti A, De Carlo F, Gargano G, Bellotti R. BMC Bioinformatics 11 500 (2010)
- Seeking for Non-Zinc-Binding MMP-2 Inhibitors: Synthesis, Biological Evaluation and Molecular Modelling Studies. Ammazzalorso A, De Filippis B, Campestre C, Laghezza A, Marrone A, Amoroso R, Tortorella P, Agamennone M. Int J Mol Sci 17 (2016)
- The N-terminal p.(Ser38Cys) TIMP3 mutation underlying Sorsby fundus dystrophy is a founder mutation disrupting an intramolecular disulfide bond. Naessens S, De Zaeytijd J, Syx D, Vandenbroucke RE, Smeets F, Van Cauwenbergh C, Leroy BP, Peelman F, Coppieters F. Hum. Mutat. 40 539-551 (2019)
- VCAN Canonical Splice Site Mutation is Associated With Vitreoretinal Degeneration and Disrupts an MMP Proteolytic Site. Tang PH, Velez G, Tsang SH, Bassuk AG, Mahajan VB. Invest. Ophthalmol. Vis. Sci. 60 282-293 (2019)
- Development of Matrix Metalloproteinase-2 Inhibitors for Cardioprotection. Bencsik P, Kupai K, Görbe A, Kenyeres É, Varga ZV, Pálóczi J, Gáspár R, Kovács L, Weber L, Takács F, Hajdú I, Fabó G, Cseh S, Barna L, Csont T, Csonka C, Dormán G, Ferdinandy P. Front Pharmacol 9 296 (2018)
- Glycosaminoglycans influence enzyme activity of MMP2 and MMP2/TIMP3 complex formation - Insights at cellular and molecular level. Ruiz-Gómez G, Vogel S, Möller S, Pisabarro MT, Hempel U. Sci Rep 9 4905 (2019)
- Molecular Docking Analysis of Phytic Acid and 4-hydroxyisoleucine as Cyclooxygenase-2, Microsomal Prostaglandin E Synthase-2, Tyrosinase, Human Neutrophil Elastase, Matrix Metalloproteinase-2 and -9, Xanthine Oxidase, Squalene Synthase, Nitric Oxide Synthase, Human Aldose Reductase, and Lipoxygenase Inhibitors. Narayanaswamy R, Wai LK, Esa NM. Pharmacogn Mag 13 S512-S518 (2017)
- Optimization of a MT1-MMP-targeting Peptide and Its Application in Near-infrared Fluorescence Tumor Imaging. Ren L, Wang Y, Zhu L, Shen L, Zhang J, Wang J, Li H, Zheng Q, Yu D, Fang X. Sci Rep 8 10334 (2018)
- Selectivity Conversion of Protease Inhibitory Antibodies. Lopez T, Ramirez A, Benitez C, Mustafa Z, Pham H, Sanchez R, Ge X. Antib Ther 1 55-63 (2018)